{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:39:02Z","timestamp":1793813942937,"version":"4.6.1"},"reference-count":94,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines & Immunotherapeutics"],"published-print":{"date-parts":[[2021,6,3]]},"DOI":"10.1080\/21645515.2020.1836919","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T11:47:51Z","timestamp":1609156071000},"page":"1586-1598","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":27,"title":["Golimumab (anti-TNF monoclonal antibody): where we stand today"],"prefix":"10.1080","volume":"17","author":[{"given":"Ana Teresa","family":"Melo","sequence":"first","affiliation":[{"name":"Hospital De Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon Academic Medical Centre","place":["Lisbon, Portugal"]},{"name":"Instituto De Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade De Medicina, Universidade De Lisboa","place":["Lisbon, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Campanilho-Marques","sequence":"additional","affiliation":[{"name":"Hospital De Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon Academic Medical Centre","place":["Lisbon, Portugal"]},{"name":"Instituto De Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade De Medicina, Universidade De Lisboa","place":["Lisbon, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Eurico","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Hospital De Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon Academic Medical Centre","place":["Lisbon, Portugal"]},{"name":"Instituto De Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade De Medicina, Universidade De Lisboa","place":["Lisbon, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,12,28]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8030387"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.12304"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.08.013"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1329009"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2016.08.014"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.01.001"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19051442"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151255"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1327576"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.01.004"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.12.025"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780340908"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00956.x"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1999.00622.x"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(93)90106-L"},{"issue":"4","key":"e_1_3_2_17_1","first-page":"393","article-title":"Golimumab, a fully human monoclonal antibody against TNFalpha","volume":"10","author":"Hutas G","year":"2008","unstructured":"Hutas G. Golimumab, a fully human monoclonal antibody against TNFalpha. Curr Opin Mol Ther. 2008 Aug;10(4):393\u2013406.","journal-title":"Curr Opin Mol Ther"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2017.1388483"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18010228"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0134-5"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0796-845"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.09.003"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2016.1106941"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/15476910490894904"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3229"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2016.1277195"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24638"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099010"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60506-7"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23969"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204195"},{"issue":"7","key":"e_1_3_2_33_1","first-page":"452","article-title":"Achieving clinical response and remission in moderate-to-severe ulcerative colitis with golimumab","volume":"10","author":"Sandborn WJ","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C. Achieving clinical response and remission in moderate-to-severe ulcerative colitis with golimumab. Gastroenterol Hepatol. 2014Jul;10(7): 452\u201354.","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.06.010"},{"key":"e_1_3_2_35_1","unstructured":"Simponi [Internet]. European medicines agency. 2018 [cited 2020 Jul 13]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/simponi"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006298188"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009340782"},{"key":"e_1_3_2_38_1","unstructured":"Clinical efficacy and safety: clinical pharmacology pharmacokinetics [Internet]. European Medicines Agency. 2018 [cited 2020 Jun 10]. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/scientific-guidelines\/clinical-efficacy-safety-clinical-pharmacology-pharmacokinetics"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S6187"},{"issue":"4","key":"e_1_3_2_40_1","first-page":"299","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: a systematic review","volume":"31","author":"Strand V","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L. et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs Clin Immunother Biopharm Gene Ther. 2017Aug;31(4): 299\u2013316.","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key309"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz003"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40226"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13291"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39257"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210456"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-018-0297-5"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34436"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204902"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216500"},{"issue":"4","key":"e_1_3_2_51_1","first-page":"CD005468","article-title":"TNF-alpha inhibitors for ankylosing spondylitis","author":"Maxwell LJ","year":"2015","unstructured":"Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MMS, Tanjong Ghogomu E, Jandu MB, Tugwell P, Wells GA. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015 Apr 18;(4):CD005468.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2015.1038300"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000396"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-018-0906-9"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1326-1"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv241"},{"issue":"3","key":"e_1_3_2_57_1","first-page":"129","article-title":"Initial experience with golimumab in clinical practice for ulcerative colitis","volume":"108","author":"Castro-Laria L","year":"2016","unstructured":"Castro-Laria L, Arg\u00fcelles-Arias F, Garc\u00eda-S\u00e1nchez V, Ben\u00edtez JM, Fern\u00e1ndez-P\u00e9rez R, Trapero-Fern\u00e1ndez AM, Gallardo-Sanchez F, Pallares-Manrique H, Gomez-Garcia M, Cabello-Tapia Mj, Talavera-Fabuel A. et al. Initial experience with golimumab in clinical practice for ulcerative colitis. Rev Espanola Enfermedades Dig Organo Of Soc Espanola Patol Dig. 2016Mar;108(3): 129\u201332.","journal-title":"Rev Espanola Enfermedades Dig Organo Of Soc Espanola Patol Dig"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i47.10432"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.15403\/jgld.2014.1121.263.trs"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001144"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1256387"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1159\/000481400"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx176"},{"key":"e_1_3_2_64_1","unstructured":"Efficacy and safety of golimumab in Crohn\u2019s disease: a French national retrospective study. Abstract - Europe PMC [Internet]. [cited 2020 Jun 20]. Available from: https:\/\/europepmc.org\/article\/med\/29027693"},{"issue":"4","key":"e_1_3_2_65_1","first-page":"652","article-title":"Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review","volume":"36","author":"Palmou-Fontana N","year":"2018","unstructured":"Palmou-Fontana N, Calvo-R\u00edo V, Mart\u00edn-Varillas JL, Fern\u00e1ndez-D\u00edaz C, Mesquida M, Ad\u00e1n A, Hernandez MV, Cordero-Coma M, Alonso OM, Diaz-Valle D, Fernandez-Cid C. Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. Clin Exp Rheumatol. 2018Aug;36(4): 652\u201357.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"e_1_3_2_66_1","first-page":"680","article-title":"Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis","volume":"37","author":"Tosi GM","year":"2019","unstructured":"Tosi GM, Sota J, Vitale A, Rigante D, Emmi G, Lopalco G, Guerriero S, Orlando I, Iannone F, Frediani B, et al. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clin Exp Rheumatol. 2019Aug;37(4): 680\u201383.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091466"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1331\/JAPhA.2009.09523"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160420"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110373"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu255"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.3.1847-1855.2001"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2019.07.003"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150057"},{"issue":"1","key":"e_1_3_2_75_1","first-page":"77","article-title":"Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors: march 2008 update","volume":"33","author":"Fonseca JE","year":"2008","unstructured":"Fonseca JE, Lucas H, Canh\u00e3o H, Duarte R, Santos MJ, Villar M, Faustino A, Raymundo E. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors: march 2008 update. Acta Reumatol Port. 2008Mar;33(1): 77\u201385.","journal-title":"Acta Reumatol Port"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1297-319X(11)70001-X"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0296-7"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110982"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.06.012"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048991"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.16071"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.12.025"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.441"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1159\/000320413"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904492"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2014.05.010"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2046"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9490-7"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000048"},{"issue":"2","key":"e_1_3_2_91_1","article-title":"Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy","volume":"14","author":"Br\u00f6ms G","year":"2016","unstructured":"Br\u00f6ms G, Granath F, Ekbom A, Hellgren K, Pedersen L, S\u00f8rensen HT, Stephansson O, Kieler H. Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2016Feb;14(2): 234\u2013241.e1\u20135.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12642"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19051349"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.05.006"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001262"}],"container-title":["Human Vaccines & Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2020.1836919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:24:51Z","timestamp":1772742291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2020.1836919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,28]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6,3]]}},"alternative-id":["10.1080\/21645515.2020.1836919"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2020.1836919","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}